Program Highlights

ICLE 2025 will showcase the most recent scientific advancements in lymphocyte engineering. It will also explore how these new findings can be used in the real world of medicine.

Take a look at the highlights below to learn more about what will be covered.

REAL-WORLD EXPERIENCE, NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES

Potential synergy b/n engineered lymphocytes & other treatment modalities will be demonstrated.

SUPERPOWERED
LYMPHOCYTES

Learn more about engineering of lymphocytes for the co-expression of varied immune effectors in addition to the transgenic receptor.

NON-VIRAL CAR/TCR GENE TARGETING

Recent advancement in promoting integrations into lymphocyte genomes by means of nucleases or transposons.

CAR/TCR MRNA
THERAPIES

Exploring the therapeutic effects of transient CAR/TCR expression using mRNA delivery.

UNIVERSAL DONOR CELLS & ADVANCED TCR ENGINEERING

A deeper look at allogeneic therapies, including those applying genome editing technologies.

UPDATED CLINICAL
DATA

First look at post marketing real world data on the approved T cell therapies.

BEYOND ALPHA-BETA
T CELLS

Discuss the engineering of alternative leukocytes including Gamma-Delta T cells, iNKT cells, NK cells, B cells and macrophages.

TARGETING NON-MALIGNANT DISEASES

Targeting of non-malignant diseases, including infectious diseases, auto-immune diseases, cardiovascular diseases, genetic disorders and more.

IN VIVO AND BEDSIDE T CELL ENGINEERING

Advancement in the scalable engineering of lymphocytes in vivo, reducing costs, timelines and pre conditioning requirements.